Literature DB >> 9374281

Reduced dopamine turnover in the basal ganglia of depressed suicides.

C Bowden1, S C Cheetham, S Lowther, C L Katona, M R Crompton, R W Horton.   

Abstract

We have measured the concentrations of dopamine, and the dopamine metabolites homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC), in five brain regions from suicide victims with a firm retrospective diagnosis of depression, and matched controls. The suicides were divided into those free of antidepressant drugs and those in whom prescription of antidepressant drugs was clearly documented. DOPAC concentrations were significantly lower in caudate, putamen and nucleus accumbens of antidepressant-free suicides compared to controls. In antidepressant-treated suicides, lower concentrations of DOPAC were observed in the basal ganglia, reaching statistical significance in caudate. Lower DOPAC concentrations were largely restricted to those suicides who died by non-violent methods. There were no significant differences in dopamine and HVA concentrations in either suicide group compared to controls, although there was a trend for HVA concentrations to be lower in suicides. This study provides evidence for reduced dopamine turnover, as judged from reduced DOPAC levels, in depressed suicides, although we cannot exclude the possibility that this may be due to ingestion of toxic agents.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9374281     DOI: 10.1016/s0006-8993(97)00692-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  21 in total

Review 1.  Potential programming of dopaminergic circuits by early life stress.

Authors:  Ana-João Rodrigues; Pedro Leão; Miguel Carvalho; Osborne F X Almeida; Nuno Sousa
Journal:  Psychopharmacology (Berl)       Date:  2010-11-19       Impact factor: 4.530

Review 2.  Stress, genes and the biology of suicidal behavior.

Authors:  Dianne Currier; J John Mann
Journal:  Psychiatr Clin North Am       Date:  2008-06

Review 3.  Toward a biosignature for suicide.

Authors:  Maria A Oquendo; Gregory M Sullivan; Katherin Sudol; Enrique Baca-Garcia; Barbara H Stanley; M Elizabeth Sublette; J John Mann
Journal:  Am J Psychiatry       Date:  2014-10-31       Impact factor: 18.112

Review 4.  An overview of the neurobiology of suicidal behaviors as one meta-system.

Authors:  M Sokolowski; J Wasserman; D Wasserman
Journal:  Mol Psychiatry       Date:  2014-09-02       Impact factor: 15.992

Review 5.  The decision neuroscience perspective on suicidal behavior: evidence and hypotheses.

Authors:  Alexandre Y Dombrovski; Michael N Hallquist
Journal:  Curr Opin Psychiatry       Date:  2017-01       Impact factor: 4.741

6.  Neurobehavioral markers of resilience to depression amongst adolescents exposed to child abuse.

Authors:  Meg J Dennison; Margaret A Sheridan; Daniel S Busso; Jessica L Jenness; Matthew Peverill; Maya L Rosen; Katie A McLaughlin
Journal:  J Abnorm Psychol       Date:  2016-11

7.  The subjective and cognitive effects of acute phenylalanine and tyrosine depletion in patients recovered from depression.

Authors:  Jonathan P Roiser; Andrew McLean; Alan D Ogilvie; Andrew D Blackwell; Diane J Bamber; Ian Goodyer; Peter B Jones; Barbara J Sahakian
Journal:  Neuropsychopharmacology       Date:  2005-04       Impact factor: 7.853

8.  Greater striatal dopamine transporter density may be associated with major depressive episode.

Authors:  Jay D Amsterdam; Andrew B Newberg; Irene Soeller; Justine Shults
Journal:  J Affect Disord       Date:  2012-04-04       Impact factor: 4.839

9.  Neither single-marker nor haplotype analyses support an association between monoamine oxidase A gene and bipolar disorder.

Authors:  San-Yuan Huang; Ming-Teng Lin; Mee-Jen Shy; Wei-Wen Lin; Fang-Yi Lin; Ru-Band Lu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04-24       Impact factor: 5.270

Review 10.  Depression, stress, and anhedonia: toward a synthesis and integrated model.

Authors:  Diego A Pizzagalli
Journal:  Annu Rev Clin Psychol       Date:  2014       Impact factor: 18.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.